During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

An international collaboration has published groundbreaking research, shedding light on the most significant increase in complexity in the history of life's evolution on Earth: the origin of the ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.